Saturday, October 31, 2015

2-year advanced melanoma survival benefit with dabrafenib, trametinib combination

›
Updated results from the COMBI-v trial show significantly improved overall and progression-free survival (OS, PFS) with first-line d...
Friday, October 30, 2015

Neurocrine Biosciences announces positive data from NBI-98854 Phase III trial in tardive dyskinesia

›
Neurocrine Biosciences, Inc. announced that NBI-98854 , a highly selective small molecule VMAT2 inhibitor, showed a statistically ...
Thursday, October 29, 2015

AcelRx Pharmaceuticals, Inc : Sufentanil

›
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization o...
Wednesday, October 28, 2015

FDA grants Breakthrough Therapy Designation to Lilly's abemaciclib for treatment of metastatic breast cancer

›
Eli Lilly  and Company (NYSE: LLY)   announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Des...
Tuesday, October 27, 2015

New drug may prevent malaria in pregnant women

›
Researchers at LSTM, working with colleagues of the Centres for Disease Control and Prevention (CDC) in Kenya and USA, and from the Kenya ...
Monday, October 26, 2015

Two studies identify promising new anti-retroviral strategy to combat HIV-1

›
A pair of studies by researchers at the University of Massachusetts Medical School, the University of Trento in Italy, and the University ...
Friday, October 23, 2015

Experimental drug shows promise in mice with multiple sclerosis

›
An experimental drug originally identified in a National Cancer Institute library of chemical compounds as a potential therapy for brain a...
Thursday, October 22, 2015

Tris Pharma announces launch of generic TUSSIONEX

›
Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced the launch of Tris-labeled ...
Wednesday, October 21, 2015

Beta-catenin shows treatment target potential for TKI-resistant CML

›
Nuclear β-catenin could be a treatment target for patients whose chronic myeloid leukaemia (CML) is resistant to tyrosine kinase inhi...
Tuesday, October 20, 2015

AbbVie reports positive results from ABT-494 Phase 2 clinical trials in patients with rheumatoid arthritis

›
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced results from two Phase 2 clinical trials evaluating its inves...
Monday, October 19, 2015

Novo Nordisk announces FDA approval of Tresiba (insulin degludec injection) for diabetes treatment

›
Novo Nordisk, a world leader in diabetes care, today announced that the U.S. Food and Drug Administration (FDA) approved the new d...
1 comment:
Friday, October 16, 2015

Allergan releases generic INVEGA (paliperidone extended-release tablets) in the U.S.

›
In continuation oof my update on  paliperidone Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced th...
Wednesday, October 14, 2015

TUM scientists develop molecules that could pave way for new treatments to fight Alzheimer's, diabetes

›
When proteins change their structure and clump together, formation of amyloid fibrils and plaques may occur. Such 'misfolding' and...
Tuesday, October 13, 2015

SMC approves Bayer's Xofigo for treatment of castration-resistant prostate cancer in NHS Scotland

›
The Scottish Medicines Consortium (SMC) has today announced that Xofigo® (radium-223 dichloride) has been accepted for use within NHS Scotla...

Patients with advanced kidney cancer benefit from cabozantinib treatment

›
In continuation of my update on cabozantinib Patients with advanced kidney cancer live for nearly twice as long without their dise...